The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type

Journal of Investigative Dermatology

Volumn 134, Issue 2, 2014, Pages 548-550

  Stadelmeyer, Elke ^a   Heitzer, Ellen ^a   Resel, Margit ^a   Cerroni, Lorenzo ^a   Wolf, Peter ^a   Dandachi, Nadia ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF V600E; BRAF V600K; DNA; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GOLD STANDARD; HUMAN; LETTER; LIMIT OF DETECTION; MALIGNANT LENTIGO; MUTATION; PHOTODERMATOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SANGER SEQUENCING; SUN EXPOSURE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; MALE; MELANOMA; MIDDLE AGED; POINT MUTATION; PREVALENCE; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84892818951     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.338     Document Type: Letter

References (22)

1. Akslen LA, Puntervoll H, Bachmann IM et al. (2008) Mutation analysis of the EGFR-NRASBRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 18:29-35
2. Cohen LM (1995) Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 33:923-36
3. Deichmann M, Thome M, Benner A et al. (2004) B-raf exon 15mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology 66:411-9
4. Hacker E, Hayward NK, Dumenil T et al. (2010) The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: Findings from an australian population. J Invest Dermatol 130:241-8
5. Hacker E, Nagore E, Cerroni L et al. (2013) NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: Findings from Spanish and Austrian populations. J Invest Dermatol 133:1027-33
6. Ichii-Nakato N, Takata M, Takayanagi S et al. (2006) High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol 126:2111-8
7. Ko JM, Fisher DE (2011) A new era: Melanoma genetics and therapeutics. J Pathol 223:241-50
8. Lang J, MacKie RM (2005) Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 125:575-9
9. Lassacher A, Worda M, Kaddu S et al. (2006) T1799A BRAF mutation is common in PUVA lentigines. J Invest Dermatol 126:1915-7
10. Maldonado JL, Fridlyand J, Patel H et al. (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878-90
11. Menzies AM, Haydu LE, Visintin L et al. (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18: 3242-9
12. Miller CJ, Cheung M, Sharma A et al. (2004) Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 123:990-2
13. Omholt K, Platz A, Kanter L et al. (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9:6483-8
14. Pollock PM, Harper UL, Hansen KS et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19-20
15. Poynter JN, Elder JT, Fullen DR et al. (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16:267-73
16. Saldanha G, Potter L, Daforno P et al. (2006) Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 12:4499-505
17. Sasaki Y, Niu C, Makino R et al. (2004) BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 123:177-83
18. Sosman JA, Kim KB, Schuchter L et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-14
19. Spittle C, Ward MR, Nathanson KL et al. (2007) Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 9:464-71
20. Stadelmeyer E (2012) Detection of BRAF mutations in lentigo maligna melanoma using a highly sensitive method. Dissertation. Medical University of Graz: Graz, Austria
21. Ugurel S, Thirumaran RK, Bloethner S et al. (2007) B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One 2:e236
22. Viros A, Fridlyand J, Bauer J et al. (2008) Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5:e120